SCHEMBL851320

SCHEMBL851320

OCCOCCOCCOCCOCCOCCOCCOCCOCc1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.58
NAAA Q02083 1/20 0.53
KDM4E B2RXH2 1/20 0.48
POLB P06746 1/20 0.48
MEN1 O00255 2/20 0.48
KMT2A Q03164 2/20 0.48
ALDH1A1 P00352 1/20 0.45
RECQL P46063 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 1/20 0.44
CA1 P00915 3/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
HTT P42858 1/20 0.44
MAPK1 P28482 1/20 0.43
IDO1 P14902 1/20 0.43
LTA4H P09960 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Triethylene Glycol SCHEMBL29103842 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL24748 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL607716 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL16437096 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL599527 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL607698 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL12865302 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL3552086 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL16437099 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1
SCHEMBL606328 1.00 TSHR (0.58) TSHRNAAAKDM4EPOLBMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022251588-A1 HETEROBIFUNCTIONAL COMPOUNDS AND METHODS OF TREATING DISEASE HALDA THERAPEUTICS OPCO, INC. (US) 2022-12-01 WO disclosed
US-11173212-B2 Supramolecular protein assemblies with advanced functions and synthesis thereof INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) 2021-11-16 US disclosed
US-11173212-B2 Supramolecular protein assemblies with advanced functions and synthesis thereof INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) 2021-11-16 US disclosed
EP-3052465-B1 POLYFUNCTIONALIZED POLYETHYLENE AND POLYPROPYLENE GLYCOL USEFUL AS TRACERS RESMAN AS (NO) 2020-07-29 EP disclosed
US-10364217-B2 Chemical compounds RESMAN AS (NO) 2019-07-30 US disclosed
EP-1594440-B1 THE SELECTIVE AND SPECIFIC PREPARATION OF DISCRETE PEG COMPOUNDS QUANTA BIODESIGN LTD (US) 2019-07-03 EP disclosed
US-20190134212-A1 SUPRAMOLECULAR PROTEIN ASSEMBLIES WITH ADVANCED FUNCTIONS AND SYNTHESIS THEREOF INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) 2019-05-09 US disclosed
US-20190134212-A1 SUPRAMOLECULAR PROTEIN ASSEMBLIES WITH ADVANCED FUNCTIONS AND SYNTHESIS THEREOF INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH (IN) 2019-05-09 US disclosed
EP-1613343-B1 INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME BIOCON LTD (IN) 2016-12-07 EP disclosed
EP-3052465-A1 CHEMICAL COMPOUNDS Resman AS (NO) 2016-08-10 EP disclosed
US-20030060606-A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2003-03-27 US disclosed
WO-2003022210-A2 PHARMACEUTICAL COMPOSITIONS OF DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH NOBEX CORPORATION (US) 2003-03-20 WO disclosed
WO-2003022996-A2 METHODS OF SYNTHESIZING INSULIN POLYPEPTIDE-OLIGOMER CONJUGATES, AND PROINSULIN POLYPEPTIDE-OLIGOMER CONJUGATES AND METHODS OF SYNTHESIZING SAME NOBEX CORPORATION (US) 2003-03-20 WO disclosed
WO-2003022208-A2 PHARMACEUTICAL COMPOSITIONS OF INSULIN DRUG-OLIGOMER CONJUGATES AND METHODS OF TREATING DISEASES THEREWITH NOBEX CORPORATION (US) 2003-03-20 WO disclosed
US-20030027748-A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2003-02-06 US disclosed
US-20030027995-A1 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same BIOCON LIMITED (IN) 2003-02-06 US disclosed
WO-2002098452-A1 MIXTURES OF GROWTH HORMONE DRUG-OLIGOMER CONJUGATES COMPROMISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed
WO-2002098446-A1 MIXTURES OF DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed
WO-2002098451-A1 MIXTURES OF CALCITONIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed
WO-2002098232-A1 MIXTURES OF INSULIN DRUG-OLIGOMER CONJUGATES COMPRISING POLYALKYLENE GLYCOL, USES THEREOF, AND METHODS OF MAKING SAME NOBEX CORPORATION (US) 2002-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190134212-A1 SUPRAMOLECULAR PROTEIN ASSEMBLIES WITH ADVANCED FUNCTIONS AND SYNTHESIS THEREOF APC, CHLSN, MAX TSHR 3255/4885NAAA 3208/4885KDM4E 4228/4885
US-20030027748-A1 Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same IAPP, SI, IDE TSHR 1412/4885NAAA 1342/4885KDM4E 4615/4885
US-20030027995-A1 Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same GHRHR, GHSR, GHITM TSHR 43/4885NAAA 1229/4885KDM4E 4494/4885
US-10364217-B2 Chemical compounds PTGES, PTGIS, PTGFR TSHR 3608/4885NAAA 2263/4885KDM4E 4601/4885
US-11173212-B2 Supramolecular protein assemblies with advanced functions and synthesis thereof APC, CHLSN, MAX TSHR 3255/4885NAAA 3208/4885KDM4E 4228/4885
US-20030060606-A1 Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same CALCB, CALCR, CALCA TSHR 1403/4885NAAA 833/4885KDM4E 4598/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.